Background and Objectives Australia introduced bacterial contamination screening (BCS) for platelet components in April 2008. This study presents analysis performed to assess the efficacy of testing.
Introduction
The Australian Red Cross Blood Service (Blood Service) has for the 6 years from January 2010 to December 2015 issued an average of 90 000 pooled platelets and 34 000 apheresis units annually. A hierarchy of measures helps reduce bacterial contamination. The donor questionnaire includes donor health questions to help exclude donors who may have infections or be at risk of asymptomatic bacteraemia. Standardized skin disinfection was introduced in 2004, followed by the introduction in October 2006 of diversion pouches that discarded the first 30 ml of blood [1] . All component processing is done in closed systems.
These measures were insufficient to prevent some septic incidents after platelet transfusion. In 2007, one patient died from a platelet transfusion contaminated with Rahnella aquatilis, and another patient recovered from a septic reaction to group B Streptococcus. Universal bacterial contamination screening (BCS) of platelets was introduced in April 2008.
Whilst all blood components can transmit bacterial contaminants, the storage of platelets at 22°C with gentle shaking promotes replication of any contaminating bacteria allowing them to achieve high concentrations. Consequently, of 15 international blood services surveyed in 2014, 10 limited storage of pooled platelets to 5 days, with 5 using 7 days [2] . Of historic blood component bacterial transmissions recorded by the United Kingdom's SHOT haemovigilance programme, 84% were in platelets [3] . It is generally accepted that bacterial testing of platelets has decreased the risk of clinical sepsis. The BacT/ ALERT 3D system is the most widely used. The manufacturer recommends that sampling be delayed at least 24 h after collection, and strongly recommends both aerobic and anaerobic cultures [4] . There is widespread variation internationally in actual practice.
Our initial experience of introducing and monitoring BCS performance until October 2010 has been previously reported [1] . In this study, we provide data on BCS performance in Australia over the 6 years from January 2010 until December 2015 and relate this to the incidence of TTBI that occurred in the period prior to the introduction of BCS and the following 7Á7-year period until December 2015. We note that measured bacterial contamination rates and residual TTBI risk are relevant in assessing the potential benefits of pathogen inactivation technologies.
Materials and methods
Bacterial contamination screening was introduced in Blood Service testing laboratories in April 2008 as described [1] . Testing used the BacT/ALERT â 3D automated microbial detection system (BioM erieux, Durham, NC, USA). Platelet components manufactured include whole-blood buffy coat-derived pooled platelets from four donations suspended in Platelet Additive Solution SSP+ ('PAS-E' manufactured by Macopharma) sampled as a pool, and apheresis platelets suspended in plasma (Gambro Trima Accel) sampled individually or pooled if a double collection. All platelet components are sampled for BCS. Closed sampling (via integrated sampling device or pouch) of 15-20 ml from each platelet component occurs at a minimum time of 24 h post-phlebotomy or 24 h post-phlebotomy of the 'youngest' buffy coat in a platelet pool, allowing any bacteria present to proliferate to potentially detectable levels. Samples of 7-10 ml each are aseptically inoculated into both aerobic and anaerobic culture bottles and incubated with continuous monitoring for 7 days (8 days post-phlebotomy). Platelets are released into inventory when culture begins as 'culture-negative to date' and have a shelf life of 5 days from phlebotomy. Components are available for issue after sampling.
Pooled platelets are manufactured from approximately half of whole-blood donations collected annually. For blood collection sites at which no platelets are manufactured in a preceding month, 1% of red cells are randomly selected for BCS testing. The use of a 7-day BCS incubation was implemented due to manufacturer recommendations [4] of a 5-to 7-day period. A shorter period of culture incubation, until platelet expiry, is currently under consideration.
When a bottle signals initial machine positive (IMP) on the BacT/ALERT system, it is removed for investigation. Any remaining companion bottle continues incubating. The unit and its associated components (red blood cells, fresh frozen plasma and cryoprecipitate) are recalled using a standard procedure by the Blood Service National Recall Office (NRO). Hospital blood banks are notified immediately, and the positive bottle is sent to an external reference laboratory (ERL) for Gram stain and organism identification. This process is expedited if the components have already been transfused, and the patient's treating clinician is notified by a Blood Service transfusion medicine specialist who undertakes clinical follow-up.
Further microbiology results are sent to the NRO who communicate them to hospital blood bank staff using standardized report forms. The treating clinician is informed via the hospital blood banks of the Gram stain, organism identification and antibiotic susceptibilities as soon as each result is available, as well as being given an information sheet relevant to the isolated organism. The time frame for organism identification and susceptibility testing depends on the growth characteristics of the organism. Standard pathogens (Staphylococcus sp. and aerobic Gram-negative organisms) take less than 48 h, but slow-growing organisms (Propionibacterium sp.) may take many days. Results are used by Blood Service medical microbiologists to determine the significance of the isolates. If an organism is deemed potentially pathogenic, Blood Service Medical Officers follow up the implicated donor(s).
Platelets with a positive culture result on resampling (or sampling of the associated red cell/plasma/cryoprecipitate component) with the same organism as the original cultures are termed 'confirmed positive' (true positive). If the original and repeat samples are Gram stain-and culture-negative, the result is classified as a 'machine-false-positive'. Red cells, cryoprecipitate and clinical plasma from these donations may only be used if they are still held in inventory. If resampling is performed and the culture is positive, but with a different organism, or if the original platelet unit or its associated components are not available for testing, an 'indeterminate' result is recorded. All recalled components from BCS confirmed positive or indeterminate incidents, or machine-false-positive components that have been recalled, are discarded.
Databases are maintained for all BCS-positive donations and the fate of each component from that donation. A separate adverse transfusion reaction reporting register is maintained allowing correlation of voluntary reports (passive surveillance) of adverse transfusion reactions with the BCS database. In Australia, there is no direct measurement of the number of platelets transfused annually; this figure was derived by using the number of platelet units issued by the Blood Service, and subtracting data for platelets discarded by Australian hospitals.
Results
The IMP rate averaged 1Á1% of units from 2010 to 2012 (Fig. 1) . Through operational improvements, the number of machine-false-positive signals was reduced to an average of 0Á6% for the years 2013 to 2015. This was achieved by distributing loading more evenly across cabinets, and following standard loading patterns that enabled bottles to be located more quickly. As a result, cabinet door opening frequency and duration was reduced, minimizing temperature fluctuations. This change was statistically significant (odds ratio 0Á56 [0Á53, 0Á59], P ≤ 0Á0001) and corresponded to a fall in the average annual number of BCS machine-false-positives from 1169 to 529. Whilst the IMP rate fell, the number of confirmed and indeterminate platelet components averaged 257 units per year (0Á17%) and remained stable (odds ratio 1Á04 [0Á93, 1Á15], P = 0Á51) after the operational improvements. The proportion of confirmed and indeterminate platelets transfused before recall remained relatively constant over 2010 to 2015, ranging from a minimum of 62% in 2011 to a maximum of 70% in 2014 (average 66%).
Pooled platelets were found to have double the rate of confirmed and indeterminate contamination, having a rate of 0Á22% for pooled platelets versus 0Á11% for apheresis platelets over the six-year period. Over this period, the percentage of double-compared to single-apheresis platelet collections rose from 50 to 74%. This difference was statistically significant with an odds ratio of 1Á90 [1Á65, 2Á18], P ≤ 0Á0001.
The types of organisms identified from confirmed episodes are shown in Table 1 . The largest groups were Propionibacterium sp. (81Á8%) and coagulase-negative Staphylococcus sp. (9Á2%). Of the confirmed positive and indeterminate platelet units that were transfused before recall, 95Á1% were contaminated with Propionibacterium sp. The majority of transfused, confirmed positive platelets contained bacteria that were low-pathogenicity skin contaminants requiring prolonged incubation times to signal positive (see Table 1 ).
Almost all pathogenic organisms flagged positive within 15 h, with the exception of Campylobacter fetus (43 h). This relatively rapid growth permitted the recall of most implicated products contaminated by virulent isolates before transfusion, and underscores the reason for the reduction of TTBIs brought about by BCS. Our data indicate a median time of issue for platelets of 2Á8 days (67 h after collection), with the majority of platelets issued after the first 18 h of incubation. Over the reported period, all platelets yielding positive cultures for aerobic Gram-negative rods or Staphylococcus aureus were successfully recalled before transfusion. The vast majority of late flagging cultures are non-pathogenic skin commensals, such as Propionibacterium sp., with a low potential for causing a TTBI. It may be argued that prolonging the incubation of BCS samples to 7 days results in detection of many such organisms with little resulting clinical benefit. Of the 426 bacterially contaminated platelet units with confirmed isolates that were transfused over 6 years, 29 per cent had some associated components also transfused. These were almost entirely associated components from platelets contaminated with Propionibacterium sp.: 99% of the red cell units (one other unit with mixed skin flora), 96% of the fresh frozen plasma units (one other unit with mixed skin flora and one other unit with Corynebacterium sp.) and 100% of the cryoprecipitate units. No TTBIs were reported from these transfused components.
Diversion pouches were introduced in October 2006, with BCS following in April 2008. During this 18-month period, there were two probable TTBIs from platelets (Table 2) , a rate of 1Á27 [0Á4, 4Á6] per 100 000 issued platelets (1Á6 [0Á4, 5Á9] per 100 000 transfused platelets). After implementation of BCS, there were three probable TTBIs over 7Á7 years, a rate of 0Á3 [0Á1, 0Á9] per 100 000 issued (0Á4 [0Á1, 1Á1] per 100 000 transfused), and a 4Á2-fold [0Á5, 28Á2] reduction in the TTBI rate for issued platelets. The three probable TTBIs from platelets were from pools that were BCS culture-negative (false negatives). The organisms subsequently isolated from the patient and implicated component were S. aureus, Bacillus cereus and coagulase-negative Staphylococcus sp., respectively. Two of these patients died from their underlying disease, and one recovered from the probable TTBI. All three patients developed symptoms consistent with TTBI during the transfusion requiring antibiotic therapy with two requiring intensive care admission. The causes of death were not considered to be related to transfusion (tumour lysis syndrome and intracranial haemorrhage, respectively).
In the 18 months prior to BCS implementation, the TTBI rate for red blood cells was 0Á10 [0Á02, 0Á55] per 100 000 issued (0Á10 [0Á02, 0Á58] per 100 000 transfused). This fell to 0Á03 [0Á01, 0Á21] per 100 000 issued (0Á04 [0Á01, 0Á21] per 100 000 transfused) after BCS, a 2Á8-fold [0Á07, 109Á0] reduction for issued red cells. The positive bacterial transmissions were only from red cells from which platelets were not manufactured and therefore not subjected to surrogate BCS, except for the 1% of red cells that are directly BCS-tested for quality control at collection sites that do not manufacture platelets. One red cell unit was contaminated with Pseudomonas putida and the other with Staphylococcus epidermidis; both patients recovered.
Discussion
An important advance has been the reduction of the IMP rate from an average of 1Á1% (2010-2012) to 0Á6% (2013) (2014) (2015) . The average number of IMP platelet units that were classified as machine-false-positive annually from 2010 to 2012 was 1169. The consequences of an IMP are multiplied in the case of pooled platelets by quarantining and recall of the four red cell, fresh frozen plasma and cryoprecipitate components associated with each platelet concentrate. From 2013 to 2015, after better controls were introduced, the number of annual false positives was reduced to 529 platelet units. Whilst machinefalse-positive components in Blood Service inventory may still be issued if within expiry date, any units that must be recalled from hospitals are discarded. Whilst the IMP rate has fallen, the percentage of confirmed and indeterminate units has remained stable at 0Á17% of total platelet units. The reduction in false positives was not associated with any decreased detection of bacterial contaminants. Our earlier published detection rates were comparable at 0Á18% [1] . Pooled platelets were found to have double the rate of confirmed and indeterminate contamination (0Á22%), as compared to apheresis platelets (0Á11%). The pooled product carries exposure to four potentially bacteraemic donors and four potentially contaminating phlebotomies, presumably accounting for the increased rate. All three probable TTBIs in platelets since the introduction of BCS were from pooled platelets; however, given 73% of issued platelets were pooled platelets, there is a higher probability that TTBIs would occur from these platelets. A 2007 German study [5] found no significant difference in the rate of confirmed positive units between apheresis and pooled platelets, whereas a recent Canadian study reported apheresis platelets had a 1Á7-fold higher rate of confirmed and indeterminate positives [6] .
Our contamination detection rate for apheresis units was 0Á11% (1100 per million). This was approximately 3Á7-fold the rate of confirmed and unconfirmed positives found by American Red Cross, who use only aerobic incubation. They reported a rate of 298 per million apheresis units distributed for the period 2007-2011 [7] . Use of both aerobic and anaerobic incubation was reported by 50% of countries surveyed in 2014 [2] . The US PASSPORT study [8] provided some support for including anaerobic incubation, given anaerobic culture identified three cases of clinically significant anaerobic bacteria. A further finding was that the contamination level detectable by BCS in apheresis platelets was approximately 1000 per million when both aerobic and anaerobic cultures were performed, similar to our rate of 1100 per million for apheresis platelets. As well as the addition of an anaerobic culture, other factors such as donor screening processes, quality of asepsis at the time of donation, use of diversion pouches, BCS sampling time post-phlebotomy, total sample volume and duration of incubation will affect the rate of positive cultures.
The finding that such a large proportion (81Á8%) of contaminating bacteria were identified as Propionibacterium sp. is likely due to the inclusion of an anaerobic bottle (it showed growth in 100% of anaerobic bottles, and just 3% of aerobic bottles), as well as 7-day culture. Staphylococcus aureus was detected more reliably by aerobic than anaerobic conditions. Pathogenic Gram-negative and Gram-positive rods were all detected in anaerobic bottles, but were variably detected in aerobic bottles inoculated with the same samples. The additional benefit of anaerobic culture was demonstrated by the identification of several pathogenic organisms, including Clostridium perfringens, Enterococcus faecalis, Streptococcus pneumoniae, Granulicatella adiacens and Campylobacter fetus that failed to grow in some, or all, aerobic culture bottles, but were detected in anaerobic cultures. These contaminated platelets and their associated components were not transfused, and represented near miss critical risk events, as these organisms can potentially cause significant morbidity and mortality in patients receiving transfusion. Previous reports include a septic reaction to S. pneumoniae contamination of red cells [9] and a reported death from transfusion of platelets contaminated with C. perfringens [10] .
It is recognized that the vast majority of bacterially contaminated components do not lead to an adverse reaction. Most bacteria identified are of questionable significance, the inoculum in the component may be low and often recipients are receiving antibiotic therapy. Of the BCS-positive platelets transfused before recall, 95Á1% were contaminated by the low-pathogenicity skin bacteria Propionibacterium sp. with no reported septic events. The lack of detection of Propionibacterium sp. before transfusion is due to the average time of platelet issue being 1Á9 days after sampling, well before the average 4Á2 days required to detect this slowly growing organism. One study of patients transfused with Propionibacterium sp. contaminated products found no evidence of sepsis [11] . However, a previous Australian report demonstrated it can cause sepsis in selected clinical situations [12] , and it is also known to produce implant-associated infections [13] .
The next largest organism group was coagulase-negative Staphylococcus sp. making up 9Á2% of confirmed contaminants, and 1Á2% of transfused, contaminated platelets. Although part of normal skin flora, and having relatively low virulence, these organisms are recognized as agents of clinically significant infection when in the bloodstream and are a common cause of bacteraemia especially in patients with underlying comorbidities and prosthetic devices [14] . Transfusion of platelets contaminated with coagulase-negative Staphylococcus sp. has previously been reported to cause fever [15] , and a transfusion contaminated with Staphylococcus lugdunensis has been reported as being fatal [16] . Contamination of a pooled platelet donation with Staphylococcus epidermidis has also been reported as inducing septic shock and death in one patient [17] .
In Australia, a 24-h sampling delay post-phlebotomy is used, with 50% of 16 countries surveyed in 2014 having sampling around this time period [2] , and in comparison with countries such as the United Kingdom where sampling is at 36-48 h. Theoretically, a longer delay between phlebotomy and sampling would enable more sensitive detection of low numbers of bacteria, reducing false-negative BCS cultures. However, this needs to be balanced against the shrinking window of platelet expiry (mandated at 5 days post-phlebotomy in Australia) and the extreme desirability of successfully recalling units identified as contaminated, especially with pathogenic bacteria, prior to transfusion. The 24-h sampling delay in Australia has been successful in preventing confirmed pathogenic bacteria from being transfused ( Table 1) .
Four large-scale independent studies from the United States, Ireland and Wales have established that the rate of bacterial contamination escaping detection by routine early culturing with BacT/ALERT is approximately 1 in 1500 units [18] . These authors then estimate, based on each patient receiving six units of apheresis platelets, that the patient risk of receiving a contaminated unit is 1:250, which correlates with an estimated septic transfusion rate of 1:1000. Despite this high predicted rate of septic transfusion reactions, haemovigilance data indicate a much lower rate of sepsis is reported. American Red Cross reports rates of post-transfusion sepsis and reported fatalities per distributed apheresis platelet unit for 2007-2011 as 1:106 931 and 1:1 015 843, respectively [7] . The sepsis rate in Australia after implementation of BCS until 2015 was 1 TTBI per 331 634 issued pooled and apheresis platelets, with no reported fatalities. The reporting of septic reactions from platelets is, however, dependent on clinicians diagnosing and reporting these reactions within a voluntary (passive) haemovigilance framework. [19] . The lower fold reduction in red cells may reflect the fact that only around half of red cells have 'surrogate' BCS testing of platelets.
Of concern was the occurrence of three BCS culturenegative products that were implicated in TTBI and were found to contain S. aureus, Bacillus cereus and coagulase-negative Staphylococcus sp. False-negative BCS results have previously been reported in TTBI cases [20] for S. aureus and coagulase-negative Staphylococcus sp. The lack of detection was ascribed to low concentrations of bacteria at the time of sampling due to a lag phase growth. Cultures did not become positive despite prolonged incubation. Another possibility is that bacteria are sequestrated in biofilm attached to the surface of the platelet bag, resulting in low planktonic bacterial count in the solution sampled for BCS. Many organisms including most Staphylococcus sp. are known to produce biofilms [21] . It is likely that in the case of the false-negative B. cereus transmission observed in this study, the bacterial concentrations were below the limit of instrument detection.
The false-negative case associated with coagulasenegative Staphylococcus sp. was categorized as a probable bacterial transmission although there was a discrepancy between the organism identified in the patient's blood culture and that identified in the red cell unit (Staphylococcus capitis and S. warneri, respectively). Staphylococcus capitis is associated with the formation of biofilms in contaminated platelet concentrates [22] that may have led to the failure to detect the organism by BCS.
The high proportion of confirmed positive and indeterminate platelets (66%) that are transfused before recall emphasizes the retrospective nature of BCS for at least some organisms. Previously reported figures of 67% [23] and of 55% [5] led to the latter authors questioning whether routine BCS can prevent contaminated products from being transfused due to the inherent delay of culture and due to false-negative results. Replacing BCS with pathogen inactivation (PI) is described as moving the blood safety paradigm from reactive to proactive [24] . Whilst high log reductions are achievable, there is the possibility of endotoxins being present should Gramnegative bacteria be inactivated at high titre. This is unlikely to occur unless the PI procedure is significantly delayed.
Until such a time as PI is available for all blood components, there is the possibility for implementation of platelet-only PI in place of BCS. In that case, recall of associated contaminated components that are currently identified by BCS would not occur. A German study reported that although the residual risk of septic transfusion reactions from red cells is estimated as being one log below that for platelets, the absolute number of transfusions was one log higher [23] . Our haemovigilance data showing two cases of TTBI from red cells since implementing platelet BCS indicate that the risk of TTBI from untested red cells remains. If BCS of platelets was replaced by PI, there would likely be an increase in TTBIs from red cells that currently have 'surrogate' testing via their platelet components (approximately half of our issue). This benefit is reduced where apheresis platelets make up the majority of platelet collections, although the risk for red cells remains.
In summary, our BCS methodology using both aerobic and anaerobic cultures has been successful in preventing the transfusion of many pathogenic organisms in platelets, and their associated components. The bulk of contaminants identified were the skin commensal Propionibacterium sp. which was related to use of anaerobic culture conditions and our prolonged 7-day incubation protocol. The reported incidence of TTBI has fallen since the introduction of BCS in 2008, with a 4Á2-fold lower rate of TTBIs from platelets and 2Á8-fold lower rate from red blood cells. In conjunction with standardized skin disinfection and diversion pouches, BCS has lowered TTBI risk, but has not eliminated it due to the occurrence of false negatives. Replacement of platelet BCS with PI would be expected to further reduce TTBIs from platelets but may increase TTBIs from untested red cells.
